Advanced Pain Diagnostic & Solutions

Curriculum Vitae
Kayvan Don Haddadan, M.D.

Licenses & Certifications

Physician & Surgeon License
Medical Board of California, License # A87957

Controlled Substance Registration Certificate
US Department of Justice, Drug Enforcement Administration, # BH8786076

Board Certified in Physical Medicine & Rehabilitation
American Board of Physical Medicine & Rehabilitation, Certificate # 8579

Board Certified in Pain Medicine
American Board of Pain Medicine, Certificate # 06409

Qualified Medical Examiner
California Department of Industrial Relations, Division of Workers' Compensation, Certificate # 129955

Education & Training

Medical Acupuncture for Physicians
University of California, Los Angeles, David Geffen School of Medicine — *12/2009 – 05/2010*
Los Angeles, CA, USA

Fellowship in Pain Medicine
California Pacific Medical Center, Pacific Pain Treatment — *01/2005 – 05/2006*
San Francisco, CA, USA

Residency in Physical Medicine & Rehabilitation
Loyola University Medical Center, Loyola University-Stritch School of Medicine — *07/2001 – 06/2004*
Maywood, IL, USA

Internship in Medical Surgery
Loyola University Medical Center, Loyola University-Stritch School of Medicine — *07/2000 – 06/2001*
Maywood, IL, USA

ECFMG Certificate
Educational Commission for Foreign Medical Graduates — *11/1998 – 04/1999*
Philadelphia, PA, USA

Medical Doctor Degree
Shahid Beheshti University of Medical Sciences — 06/1991 – 06/1995
Tehran, Iran

Bachelor of Science Degree
College of Alborz — *09/1987 – 05/1991*
Tehran, Iran

Employment

President & Medical Director
Advanced Pain Diagnostic & Solutions, Inc., Roseville CA *3/2012 — Present*

Pain Management Physician/Physiatrist
Allmed Medical Group, Sacramento CA *01/2011 – 03/2013*

Pain Management Physician/Physiatrist
Woodland Healthcare, Orthopedic/Pain Medicine Department, Woodland, CA *12/2007 – 12/2010*

Pain Management Physician/Physiatrist
Institute of Restorative Health, Davis CA *06/2006 – 12/2007*

Pain Management Physician/Physiatrist
Janet Lord, M.D. & Associates, Berkley CA *06/2006 – 12/2007*

Pain Management Physician/Physiatrist
Spine Pain Diagnostic Associates, Niagara WI *08/2004 – 12/2004*

Chief Resident, PM&R Dept.
Loyola University Medical Center *07/2003 – 07/2004*

Clinical Research Experience

Cardiology-Hyperlipidemia

- LTS11717: Long-Term safety and tolerability of XXXX in high cardiovascular risk patients with hypercholesterolemia not adequately controlled with their lipid modifying therapy: a randomized, double-blind, placebo-controlled study.

Cardiovascular/Endocrine - Hyperuricemia

- TMX-67-301: A Multicenter, Randomized, Double-Blind, Phase 3B Study to Evaluate the Cardiovascular Safety of XXXX and XXXX in Subjects with Gout and Cardiovascular Comorbidities.

Endocrinology -Diabetes

- B102-073: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of XXXX in Subjects with Type 2 Diabetes with inadequately controlled hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB).
- MB102-077: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of XXXX in Subjects with Type 2 Diabetes with inadequately controlled hypertension treated with an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and an additional Antihypertensive medication.
- 1218.83: A 24-week, randomized, double-blind, active-controlled, parallel group trial to assess the superiority of oral XXXX and XXXX compared to XXXX in newly diagnosed, treatment-naïve, uncontrolled Type 2 Diabetes Mellitus patients.
- 1218.80: A Cross-Sectional Evaluation of Type II Diabetes and Associated Chronic Kidney Disease in the Primary Care Setting.

Endocrinology- Hyperuricemia

- RDEA594-302: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Safety and Efficacy of XXXX and)000: Compared to *XXXX* alone in Subjects with Gout who have had an Inadequate Hypouricemic Response to Standard of Care XXXX.
- RDEA594-306: A Long-Term Extension Study of XXX in Combination with XXX for Subjects completing an Efficacy and Safety Study of XXX and XXX.
- RDEA3170-201: A Phase 2 Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXX Monotherapy in Subjects with Gout.

Infectious Disease

- T705aUS317: A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Safety and Efficacy of XXXX in Adult Subjects with Uncomplicated Influenza.

Pain Management

- ONU3704: A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of XXXX to Assess the Analgesic Efficacy and the Management of Opioid-induced Constipation in Opioid-experienced Subjects with Uncontrolled Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the-clock Opioid Therapy.
- 1315V9232: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of XXXX in the Treatment of Opioid-induced Constipation in Subjects with Non-Malignant Chronic Pain Receiving Opioid Therapy.
- 6603/1131: A Multicenter, Randomized, Double-blind, Controlled, Comparative Study of XXX Patients with Lumbar Disc Herniation (Phase III).
- Outcome Measurement in patients with Spinal cord stimulator, K.D. Haddadan, M.D., E.S. Krames, M.D., Journal of Neruomodulation.
- Poster presentation: Neuropathic pain management of lower Extremity using Sciatic nerve block: case report. Presented in AAPM, Orlando, FL, March 2004. Won the 2004 AAPM Scientific poster award.
- Poster presentation: Risk factors of Peroneal Neuropathy. Presented in AAEM meeting in San Francisco, CA September 2003. Won the best research award in the residency program.
- Poster presentation: Rehabilitation of patient with Dual disability of Total Knee Arthroplasty and Below Knee amputation, 2 case reports. Presented in AAPM&R Academy meeting, Orlando, FL in October 2002.

Pulmonology

- C38072-3084: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX Treatment in Patients With Moderate to Severe Asthma.
- LAC-MD-31: A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of XXXX Compared with XXXX and XXXX for 24-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD).

- LAC-MD-36: A Phase III, Long-Term, Randomized, Double-Blind, Extension Study of the Efficacy, Safety and Tolerability of XXXX, XXXX, XXXX and XXXX for 28-Weeks Treatment in Patients with Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD).
- ROF-MD-07: A 52-week, Double-Blind, Randomized, Placebo (Controlled Parallel Group Study to Evaluate the Effect of XXXX on Exacerbation Rate in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Treated with XXXX and XXXX.
- SAS115359: A Safety and Efficacy Study of XXXX versus XXXX in the Treatment of Adolescent and Adult Subjects with Asthma.
- HZC113782: A Clinical Outcomes Study to compare the effect of XXXX with XXXX on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular.
- LAS-MD-45: Double-Blind, Randomized, Placebo Controlled, Parallel Group, Phase IV Study to Evaluate the Effect of XXXX on Long Term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD.
- 17003007: Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of XXX, XXX, and XXX in Subjects with Moderate to Very Severe COPD, Compared with Placebo.
- 201-085: A Randomized, Double-blind, Placebo-controlled Study of Long-term Use of X.) in Subjects with Chronic Obstructive Pulmonary Disease (COPD).

Gastroenterology

- NAK-07: A 52-week, Double-Blind, Randomized, Placebo Controlled Parallel Group Phase III Study with Re-Randomization at week 25 to Evaluate the Efficacy and Safety of XXX Once Daily in Female Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D).
- 270189661B53001: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome.